Back to Search Start Over

Myelin oligodendrocyte glycoprotein (MOG) associated optic neuritis in a patient with idiopathic intracranial hypertension (IIH) and compressive optic neuropathy case report.

Authors :
Sorensen RD
Vogt A
Laylani N
Pakravan M
Lee AG
Source :
BMC ophthalmology [BMC Ophthalmol] 2024 Feb 13; Vol. 24 (1), pp. 61. Date of Electronic Publication: 2024 Feb 13.
Publication Year :
2024

Abstract

Background: Myelin oligodendrocyte glycoprotein-associated disease (MOGAD) has a wide phenotypic expression and should be considered in a differential diagnosis of patients with optic disc edema and increased intracranial pressure because MOGAD can mimic IIH and compressive optic neuropathy.<br />Case Presentation: A 53-year-old woman with a history of presumed idiopathic intracranial hypertension ("IIH") presented with new headache and visual loss. She had a BMI of 35.44 kg/m2 and a past medical history significant for depression, hepatitis C, hyperlipidemia, and uterine cancer post-hysterectomy. She had undergone multiple lumboperitoneal shunts for presumed IIH and had a prior pituitary adenoma resection. Her visual acuity was no light perception OD and counting fingers OS. After neuro-ophthalmic consultation, a repeat cranial MRI showed symmetric thin peripheral optic nerve sheath enhancement of the intra-orbital optic nerves OU. Serum MOG antibody was positive at 1:100 and she was treated with intravenous steroids followed by plasma exchange and rituximab.<br />Conclusions: This case highlights the importance of considering MOGAD in the differential diagnosis of optic neuropathy. Although likely multifactorial, we believe that the lack of improvement in our case from presumed IIH and despite adequate neurosurgical decompression of a pituitary adenoma with compression of the optic apparatus reflected underlying unrecognized MOGAD. Clinicians should consider repeat imaging of the orbit (in addition to the head) in cases of atypical IIH or compressive optic neuropathy especially when the clinical course or response to therapy is poor or progressive.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1471-2415
Volume :
24
Issue :
1
Database :
MEDLINE
Journal :
BMC ophthalmology
Publication Type :
Academic Journal
Accession number :
38350984
Full Text :
https://doi.org/10.1186/s12886-023-03280-x